Literature DB >> 7747085

Bacteremia in HIV-positive and AIDS patients: incidence, species distribution, risk-factors, outcome, and influence of long-term prophylactic antibiotic treatment.

C N Meyer1, P Skinhøj, J Prag.   

Abstract

From a cohort of 837 adult, mainly homosexual HIV-infected patients, 76 bacteremic/fungemic episodes were identified in 63 patients over a 5-year period. Compared with an age-matched reference population with an incidence of 10.3 bacteremias/10,000 person-years, the incidence was 170 among pre-AIDS (p < 0.001) and 3,200 among AIDS patients (p < 0.001). Staphylococcal infections comprised 35% of all episodes, while the HIV-related pathogens Streptococcus pneumoniae, Salmonella spp. and C. neoformans together accounted for 34%. The overall mortality associated with clinical bacteremia was 12%, but nil for Salmonella spp. and S. pneumoniae. Predisposing factors for the infection were: low CD4 count (< 100 x 10(6)/l) in 71%, permanent intravenous line, 44%; neutropenia, 11% and active intravenous drug abuse, 7%. Hence, in this population, intensified hygienic precautions for intravenous lines should be the primary target for intervention. Long-term cotrimoxazole prophylaxis may prevent bacteremia with S. pneumoniae and Salmonella spp.

Entities:  

Mesh:

Year:  1994        PMID: 7747085     DOI: 10.3109/00365549409008630

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

1.  Coma during Salmonella typhimurium septicaemia.

Authors:  F Leibinger; J M Guerin; A Mofredj
Journal:  Postgrad Med J       Date:  1997-09       Impact factor: 2.401

2.  Lower respiratory tract infections among HIV positive and control group in Nepal.

Authors:  Chet Raj Ojha; N Rijal; K C Khagendra; K Palpasa; P Kansakar; B P Gupta; G Shakya
Journal:  Virusdisease       Date:  2015-06-23

3.  Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia.

Authors:  David A Wininger; Robert J Fass
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey.

Authors:  R Manfredi; A Nanetti; M Ferri; F Chiodo
Journal:  Eur J Epidemiol       Date:  2000-02       Impact factor: 8.082

Review 5.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

6.  Emergence of antibiotic resistance in immunocompromised host populations: A case study of emerging antibiotic resistant tuberculosis in AIDS patients.

Authors:  Ashley A DeNegre; Martial L Ndeffo Mbah; Kellen Myers; Nina H Fefferman
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

7.  Impact of chemorophylaxis policy for AIDS-immunocompromised patients on emergence of bacterial resistance.

Authors:  Ashley A DeNegre; Kellen Myers; Nina H Fefferman
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

8.  High prevalence of Non-typhoid salmonella bacteraemia among febrile HIV adult patients admitted at a tertiary Hospital, North-Western Tanzania.

Authors:  Alfred Meremo; Stephen E Mshana; Benson R Kidenya; Rodrick Kabangila; Robert Peck; Johannes B Kataraihya
Journal:  Int Arch Med       Date:  2012-10-17

9.  Bacteremia in hospitalized patients with human immunodeficiency virus: A prospective, cohort study.

Authors:  B Afessa; I Morales; B Weaver
Journal:  BMC Infect Dis       Date:  2001-09-07       Impact factor: 3.090

10.  Antibiotic Resistance Characterization of Environmental E. coli Isolated from River Mula-Mutha, Pune District, India.

Authors:  Rutuja Dhawde; Ragini Macaden; Dhananjaya Saranath; Kayzad Nilgiriwala; Appasaheb Ghadge; Tannaz Birdi
Journal:  Int J Environ Res Public Health       Date:  2018-06-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.